A Pragmatist’s View on Biomarker-Driven Decisions in Oncology: Episode 1
Website: https://www.onclive.comTwitter: https://twitter.com/OncLiveFacebook: https://www.facebook.com/OncLive/LinkedIn: https://www.linkedin.com/company/onc…
Related Articles
Stressing the importance of circadian time in treatment responses
Circadian disruption increases cancer risk, but connections between circadian clocks and cancer biology are diverse and depend on tumor type. In this issue of Cancer…
Medical expert explains how trauma can impact heart health
Trauma doesn’t just affect the mind—it impacts the heart too. On @9news, I’m breaking down how traumatic events, like the recent LA wildfires, can take…
What is Cardio-Oncology?
Have you been diagnosed with cancer and now been told that you need to be seen by a cardiologist or a cardio-oncologist? In this video…
Dr van den Brink on a High-Fiber Dietary Intervention in Smoldering Multiple Myeloma
Marcel van den Brink, MD, PhD, discusses a high-fiber dietary intervention for early-stage plasma cell disorders designed for multiple myeloma
Adjuvant Cemiplimab Improves DFS in High-Risk CSCC
The C-POST trial has shown cemiplimab to significantly improve disease-free survival in patients with high-risk cutaneous squamous cell carcinoma following surgery.
Hand therapy interventions for the prevention of chemotherapy-induced peripheral neuropathy of the hands in patients with pancreatic cancer
This trial compared investigational hand therapy intervention with a traditional occupational therapy approach to prevent chemotherapy-induced peripheral n
Reviewing the Options for Bladder Cancer in Different Settings
Matthew R. Zibelman, MD, discusses treatment options in muscle-invasive, perioperative, and metastatic bladder cancer.
Ep. 7 Vulnerable Trial
Ep. 7 Vulnerable trial. Podcast acerca del tratamiento de placas vulnerables no siginificativas
